Earnings Preview: Eli Lilly

Eli Lilly (LLY) is expected to report Q1 earnings prior to market open Monday, with a conference call scheduled for Monday,April 21 at 9:00 am ET.

Guidance

Analysts are looking for a profit of 96c on revenue of 4.82B. The consensus range is 88c to 98c for EPS, and revenue of $4.6B to $4.91B, according to First Call.

The Zyprexa fallout has been the main negative driver for the stock lately, because sales of Zyprexa account for 25% of Lilly's revenue. Lilly and federal prosecutors are discussing a settlement of a civil and criminal investigation into the company's marketing of the anti-psychotic drug that could result in Lilly's paying more than $1B. The drug company recently settled a Zyprexa lawsuit with Alaska for $15M.

Analyst Views

Bear Stearns noted that it expects EPS growth of 12% for a handful of pharmaceuticals, including Lilly.

In February Goldman Sachs upgraded the major pharmaceuticals on valuation.

Comments

[DannyHaszard]

9+ more states still to deal on Zyprexa suits.
The settlement with the feds could top $1 billion.
Eli Lilly has 'promised' a $1.2 billion personal injury settlement with individual claimants like myself who have NOT been paid yet.

Zyprexa remains on the market in the United States and more than 80 other countries.

About 30 state attorneys general have subpoenaed documents detailing Lilly's sales practices for Zyprexa as part of a civil investigation under state consumer protection laws.
I took Zyprexa for 4 years 1996-2000 (before the black box warning) at $250 a month co-pay.I got a shocking BG (blood sugar) of 500 in 2000.My doctors say it WAS the Zyprexa that caused it.I have NO diabetes in my family.
Moreover,I was given it off-label for PTSD.

Daniel Haszard zyprexa-victims.com